Search Results - "Höchsmann, Britta"

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria by Hillmen, Peter, Szer, Jeff, Weitz, Ilene, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos, Nishimori, Hisakazu, Tan, Lisa, Hamdani, Mohamed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Ajayi, Temitayo, Risitano, Antonio, de la Tour, Régis Peffault

“…Anemia associated with PNH is caused by hemolysis. The C5 inhibitor eculizumab blocks intravascular hemolysis, but anemia often persists owing to extravascular…”
Get full text

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation by Harder, Markus J., Kuhn, Nadine, Schrezenmeier, Hubert, Höchsmann, Britta, von Zabern, Inge, Weinstock, Christof, Simmet, Thomas, Ricklin, Daniel, Lambris, John D., Skerra, Arne, Anliker, Markus, Schmidt, Christoph Q.

“…Eculizumab inhibits the terminal, lytic pathway of complement by blocking the activation of the complement protein C5 and shows remarkable clinical benefits in…”
Get full text

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria by Kelly, Richard J, Höchsmann, Britta, Szer, Jeff, Kulasekararaj, Austin, de Guibert, Sophie, Röth, Alexander, Weitz, Ilene C, Armstrong, Elina, Risitano, Antonio M, Patriquin, Christopher J, Terriou, Louis, Muus, Petra, Hill, Anita, Turner, Michelle P, Schrezenmeier, Hubert, Peffault de Latour, Regis

“…Pregnancy has been discouraged in patients with paroxysmal nocturnal hemoglobinuria, a life-threatening hemolytic anemia, because of the heightened risk…”
Get full text

Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation by Höchsmann, Britta, Murakami, Yoshiko, Osato, Makiko, Knaus, Alexej, Kawamoto, Michi, Inoue, Norimitsu, Hirata, Tetsuya, Murata, Shogo, Anliker, Markus, Eggermann, Thomas, Jäger, Marten, Floettmann, Ricarda, Höllein, Alexander, Murase, Sho, Ueda, Yasutaka, Nishimura, Jun-Ichi, Kanakura, Yuzuru, Kohara, Nobuo, Schrezenmeier, Hubert, Krawitz, Peter M, Kinoshita, Taroh

“…Patients with paroxysmal nocturnal hemoglobinuria (PNH) have a clonal population of blood cells deficient in glycosylphosphatidylinositol-anchored…”
Get full text

Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT) by ElGohary, Ghada, El Fakih, Riad, de Latour, Regis, Risitano, Antonio, Marsh, Judith, Schrezenmeier, Hubert, Gluckman, Eliane, Höchsmann, Britta, Pierri, Filomena, Halkes, Constantijn, Alzahrani, Hazzaa, De la Fuente, Josu, Cesaro, Simone, Alahmari, Ali, Ahmed, Syed Osman, Passweg, Jakob, Dufour, Carlo, Bacigalupo, Andrea, Aljurf, Mahmoud

“…Aplastic anemia (AA) is a serious hematological disorder, which is solely cured by hematopoietic stem cell transplantation (HSCT). Haploidentical HSCT is an…”
Get full text

Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction by Muckenthaler, Lena, Marques, Oriana, Colucci, Silvia, Kunz, Joachim, Fabrowski, Piotr, Bast, Thomas, Altamura, Sandro, Höchsmann, Britta, Schrezenmeier, Hubert, Langlotz, Monika, Richter-Pechanska, Paulina, Rausch, Tobias, Hofmeister-Mielke, Nicole, Gunkel, Nikolas, Hentze, Matthias W., Kulozik, Andreas E., Muckenthaler, Martina U.

“…Muckenthaler et al describe a novel form of hemochromatosis caused by a constitutional PIGA mutation in 3 children with associated neurologic dysfunction…”
Get full text

Targeted Therapy with Eculizumab for Inherited CD59 Deficiency by Höchsmann, Britta, Dohna-Schwake, Christian, Kyrieleis, Henriette A, Pannicke, Ulrich, Schrezenmeier, Hubert

“…Patients with CD59 deficiency have progressive neurologic dysfunction and episodes of hemolytic anemia. Eculizumab, a complement inhibitor, was administered to…”
Get full text

Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces by Dopler, Arthur, Stibitzky, Selina, Hevey, Rachel, Mannes, Marco, Guariento, Mara, Höchsmann, Britta, Schrezenmeier, Hubert, Ricklin, Daniel, Schmidt, Christoph Q

“…To discriminate between self and non-self surfaces and facilitate immune surveillance, the complement system relies on the interplay between surface-directed…”
Get full text

Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation by Tichelli, André, de Latour, Régis Peffault, Passweg, Jakob, Knol-Bout, Cora, Socié, Gérard, Marsh, Judith, Schrezenmeier, Hubert, Höchsmann, Britta, Bacigalupo, Andrea, Samarasinghe, Sujith, Rovó, Alicia, Kulasekararaj, Austin, Röth, Alexander, Eikema, Dirk-Jan, Bosman, Paul, Bader, Peter, Risitano, Antonio, Dufour, Carlo

“…This follow-up study of a randomized, prospective trial included 192 patients with newly diagnosed severe aplastic anemia receiving antithymoglobulin and…”
Get full text

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial by de Latour, Régis Peffault, Szer, Jeff, Weitz, Ilene C, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos M, Nishimori, Hisakazu, Ajayi, Temitayo, Al-Adhami, Mohammed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Risitano, Antonio M, Hillmen, Peter

“…BACKGROUNDIn the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult…”
Get full text

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria by Hillmen, Peter, Szer, Jeff, Weitz, Ilene, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos, Nishimori, Hisakazu, Tan, Lisa, Hamdani, Mohamed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Ajayi, Temitayo, Risitano, Antonio, Peffault de Latour, Régis

Get full text

Response to Comment on "Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1" by Dopler, Arthur, Guntau, Leonie, Harder, Markus J, Palmer, Annette, Höchsmann, Britta, Schrezenmeier, Hubert, Simmet, Thomas, Huber-Lang, Markus, Schmidt, Christoph Q

Get full text

Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion by Weinstock, Christof, Möhle, Robert, Dorn, Christiane, Weisel, Katja, Höchsmann, Britta, Schrezenmeier, Hubert, Kanz, Lothar

“…Background Transfusion of ABO major–incompatible red blood cells (RBCs) can activate the complement system and can cause severe and even lethal acute hemolytic…”
Get full text

Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation by Harder, Markus J, Anliker, Markus, Höchsmann, Britta, Simmet, Thomas, Huber-Lang, Markus, Schrezenmeier, Hubert, Ricklin, Daniel, Lambris, John D, Barlow, Paul N, Schmidt, Christoph Q

“…The serum proteins factor H (FH), consisting of 20 complement control protein modules (CCPs), and its splice product FH-like protein 1 (FHL-1; consisting of…”
Get full text

A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT by Krawitz, Peter M., Höchsmann, Britta, Murakami, Yoshiko, Teubner, Britta, Krüger, Ulrike, Klopocki, Eva, Neitzel, Heidemarie, Hoellein, Alexander, Schneider, Christina, Parkhomchuk, Dmitri, Hecht, Jochen, Robinson, Peter N., Mundlos, Stefan, Kinoshita, Taroh, Schrezenmeier, Hubert

“…To ascertain the genetic basis of a paroxysmal nocturnal hemoglobinuria (PNH) case without somatic mutations in PIGA, we performed deep next-generation…”
Get full text

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients by Harder, Markus J, Höchsmann, Britta, Dopler, Arthur, Anliker, Markus, Weinstock, Christof, Skerra, Arne, Simmet, Thomas, Schrezenmeier, Hubert, Schmidt, Christoph Q

“…Eculizumab blocks the lytic complement pathway by inhibiting C5 and has become the standard of care for certain complement-mediated diseases. Previously, we…”
Get full text

Congenital CD59 Deficiency by Höchsmann, Britta, MD, Schrezenmeier, Hubert, MD

“…The severe clinical symptoms of inherited CD59 deficiency confirm the importance of CD59 as essential complement regulatory protein for protection of cells…”
Get full text

Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets by Schrezenmeier, Hubert, Walther-Wenke, Gabriele, Müller, Thomas H., Weinauer, Franz, Younis, Adelheid, Holland-Letz, Tim, Geis, Gabriele, Asmus, Jens, Bauerfeind, Ursula, Burkhart, Jürgen, Deitenbeck, Robert, Förstemann, Elisabeth, Gebauer, Wolfgang, Höchsmann, Britta, Karakassopoulos, Apostolos, Liebscher, Ute-Maja, Sänger, Werner, Schmidt, Michael, Schunter, Friedrich, Sireis, Walid, Seifried, Erhard

“…BACKGROUND: The GERMS Group initiated a prospective multicenter study to assess prevalence and nature of bacterial contamination of pooled buffy‐coat platelet…”
Get full text

A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patient by Anliker, Markus, von Zabern, Inge, Höchsmann, Britta, Kyrieleis, Henriette, Dohna-Schwake, Christian, Flegel, Willy A., Schrezenmeier, Hubert, Weinstock, Christof

“…Background CD59 is a cell surface glycoprotein of approximately 20 kDa limiting the lytic activity of the terminal complement complex C5b‐9. Although CD59 is…”
Get full text

Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation by Alotaibi, Hind, Aljurf, Mahmoud, de Latour, Regis, Alfayez, Mansour, Bacigalupo, Andrea, Fakih, Riad El, Schrezenmeier, Hubert, Ahmed, Syed Osman, Gluckman, Eliane, Iqbal, Shahid, Höchsmann, Britta, Halkes, Constantijn, de la Fuente, Josu, Alshehry, Nawal, Cesaro, Simone, Passweg, Jakob, Dufour, Carlo, Risitano, Antonio M., DiPersio, John, Motabi, Ibraheem

“…•Hematopoietic stem cell transplantation from a matched sibling donor (MSD) is the standard of care treatment for children and young adults with severe…”
Get full text